Clinical trial
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian…
NCT00003439 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003439 |
|---|---|
| Title | Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer |
| Official title | A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12 |
| Enrollment | 36 |
| Start date | Aug 1, 1998 |
| Primary completion | May 1, 2001 |
| First posted | May 20, 2004 |
| Last update posted | Feb 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: